INTRODUCTION
sixth day, using recombinant mouse CCL11 (R & D System®, McKinley Place NE, 142 Minneapolis, USA), reconstituted in 100 μg/mL of phosphate-buffered saline (PBS, pH 7.2) 143 containing 1% bovine serum albumin. CCL11 (0.08 pmol/kg) was injected into the air pouch 144 of each animal and the exudates were harvested 4 hours post-injection (32, 33) . The control 145 group received 100 μL of sterile PBS per animal.
146
Next, we investigated the dose of the CCR3 receptor antagonist, SB 328437 (Tocris®, 147 Avonmouth, Bristol, United Kingdom) required to block eosinophil migration to the air pouch 148 in response to CCL11. SB 328437 was dissolved in PBS and Tween 80 (0.1%) and doses of 1, 
155
Total leukocyte number was determined in a Neubauer chamber and differential 156 leukocyte count was performed in a cytospin preparation stained with hematoxylin-eosin for oil (S.O; Merck®, Darmstadt, Germany) (in volume of 60 μL). The animals had their uterus, 166 spleen, diaphragm and bladder removed and weighed.
167
For the dose response experiment, the same procedure for E2 injection was followed 168 using doses of 0.1, 1, 10 and 100 μg/kg, and organ collection was performed at the optimal 169 time as indicated in the time-response experiments.
170
Effect of SB 328437 on eosinophil migration to uterus 171 In order to investigate the effect of the CCR3 antagonism on eosinophil migration to 172 uterus, a group of mice received SB 328437 (i.p) and 30 minutes later E2 (100 µg/kg) was in the experiments to promote increased weight of the uterus, the uterus was collected, 176 cleaned, weighed and photographed.
177
Evaluation of eosinophil migration was estimated by measuring eosinophil peroxidase 178 activity analysis and cell counting in tissue sections stained with orcein as described below. with a Potter homogenizer. The homogenate was centrifuged at 440 x g, 4°C for 15 minutes.
186
The supernatant was discarded and the pellet was resuspended with the same solution and 187 centrifuged under the same conditions. Subsequently the pellet was resuspended in PBS 188 solution and hexadecyltrimethylammonium bromide (HTAB, 0.5%) in a ratio of 1.9 mL/100 189 mg of tissue and further centrifuged at 3000 x g for 15 minutes at 4°C.
RESULTS

215
Time and dose-response curve of E2-induced uterus edema
216
To determine the time and dose dependence of E2-induced uterine edema, the wet 217 weight of the uterus was measured. The weight of other organs was also determined: bladder, 218 adjacent to the reproductive tract; spleen, as a lymphoid organ; and diaphragm, representing a 219 close muscle region of the lung. We demonstrated that after 24 hours, the E2-injected animals 220 (100 μg/kg) presented significant uterine edema, causing increase of 68% in uterus weight 221 compared with group that received only sesame oil (S.O; Figure 1A ). Furthermore, different 222 doses (0.1, 1, 10 and 100 μg/kg) were tested and the E2 doses of 1, 10 and 100 μg/kg were 223 effective in inducing uterine edema 24 h after E2 administration. Nevertheless, the E2 dose of 224 100 μg/kg was the more effective, increasing organ weight by 67% ( Figure 1B ). However, μg/kg increased (53%) EPO activity ( Figure 2B ).
233
CCR3 antagonist (SB 328437) inhibits eosinophils migration to air pouch model 234
Initially, the air pouch model was used to determine the dose of the CCR3 antagonist 235 capable of inhibiting eosinophil migration to the pouch in response to CCL11 (0.08 pmol).
236
CCL11 increased the total leukocyte migration into the air pouch ( Figure 3A) , and among 237 these leukocytes, the number of eosinophils that migrated was greater in relation to neutrophils and mononuclear cells ( Figure 3B-D) . In contrast, eosinophils migration to the air 239 pouch decreased in animals treated with CCR3 antagonist at dose of 3 mg/kg or 10 mg/kg 240 ( Figure 3B ). Interestingly, the CCR3 antagonist failed to affect the number of neutrophil and 241 mononuclear cells that migrated to the pouch after CCL11 injection ( Figure 3C-D) .
242
E2-induced uterine edema is inhibited by administration of the CCR3 antagonist
243
The dose of 3 mg/kg was used for the further experiments. As shown in Figure 4A , the 244 CCR3 antagonist prevented by 46% the uterine weight gain compared to E2-injected group.
245
In addition, there was no change in weight of bladder, spleen and diaphragm ( Figure 4B-D) . 
DISCUSSION
263
The findings of our study demonstrated that CCR3 antagonist was able to inhibit the increased migration of eosinophils in our study, because it is down-regulated by E2 (51).
291
It is known that, in uterus mice, cells express nuclear estrogen receptors (54) Data are expressed as mean and SEM of 2 independent experiments and all data were analyzed using one-way After 24 hours, the uterus was collected and EPO activity was monitored as the absorbance at 492 nm. Data are expressed as mean and SEM of 2 independent experiments and all data were analyzed using one-way ANOVAs with Bonferroni post hoc correction, with (n = 5/group each), with # P <0.05 compared to the S.O group and * P < 0.05 compared to the E2 group. 
